New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
07:13 EDTVVUS, AUXLVIVUS and Auxilium announces FDA accepted STENDRA's supplemental application
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has accepted a supplemental application that proposes to revise the STENDRA, or avanafil, prescribing information with efficacy and safety information from Study TA-501, entitled "A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men with Erectile Dysfunction." The PDUFA date for the supplemental filing is September 20.
News For VVUS;AUXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
08:13 EDTAUXLBioSpecifics announces FDA approval of sBLA for XIAFLEX
Subscribe for More Information
October 20, 2014
17:33 EDTAUXLAuxilium announces XIAFLEX approved for treatment of up to two DC joints
Subscribe for More Information
October 13, 2014
06:41 EDTAUXLEndo upgraded to Hold from Sell at Cantor
Subscribe for More Information
October 10, 2014
11:18 EDTAUXLOptions with decreasing implied volatility
Subscribe for More Information
10:01 EDTAUXLOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:35 EDTAUXLAuxilium downgraded to Neutral from Buy at MKM Partners
Subscribe for More Information
05:50 EDTAUXLEndo upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Endo (ENDP) to Overweight with an $84 price target citing an improved asset base following the takeover of Auxilium (AUXL).
05:47 EDTAUXLAuxilium downgraded to Neutral from Buy at Mizuho
Mizuho downgraded Auxilium (AUXL) to Neutral following the company's agreement to be acquired by Endo (ENDP). The firm expects shareholders to approve the deal and does not expect a competing bid.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use